News & Insights
Official updates, press releases, and original thought leadership from the AltrixBio team
News & Press Releases
09/15/2025
AltrixBio Raises $5 Million Series A Financing and Appoints David Pass as CEO to Advance Lead Candidate into the Clinic
08/25/2022
LuCI - Researchers present a Potentially Novel Anti-obesity Therapy for Obesity-associated Type 2 Diabetes (T2D) abstract at the International Federation for Surgery of Obesity and Metabolic Disorders (IFSO) Conference
AltrixBio Named as a Top 10 Biotech Startup of 2021 by Pharma Tech Outlook.
Coming Soon:
News- 09/17/2025 David Pass, CEO, to present and attend at Obesity Science and Innovation meeting in Boston
News- 10/13-30/2025 David Pass, CEO, to present and attend at BioFuture in New York
News- 10/28-30/2025 AltrixBio will be a “Start-Up Showcase” and attend at the Diabetes Technology Meeting in San Francisco
Media inquiries? Contact our team:
Thought Leadership
Preclinical Publications
LuCI Acute Results
- Lee Y, Deelman T, Chen Keyue, Lin Dawn, Tavakkoli Ali, and Karp, Jeffrey. Therapeutic luminal coating of the intestine, Nature Materials, 1018 June 10.1038/s41563-018- 0106-5.
LuCI Chronic Results
- Lo T, Lee Y, Tseng CY, Hu Y, Connelly MA, Mantzoros CS, Karp JM, Tavakkoli A. Daily transient coating of the intestine leads to weight loss and improved glucose tolerance. Metabolism. 2022 Jan;126:154917. doi: 10.1016/j.metabol.2021.154917. Epub 2021 Oct 21. PMID: 34687727; PMCID: PMC8666968.
References
- Courcoulas AP, Yanovski SZ, Bonds D, Eggerman TL, Horlick M, Staten MA, Arterburn DE. Long-term outcomes of bariatric surgery: a National Institutes of Health symposium. JAMA Surg. 2014 Dec;149(12):1323-9. doi:10.1001/jamasurg.2014.2440. PMID: 25271405; PMCID: PMC5570469.
- Lee Y, Deelman TE, Chen K, Lin DSY, Tavakkoli A, Karp JM. Therapeutic luminal coating of the intestine. Nat Mater. 2018;17(10):957-63. doi:10.1038/s41563-018-0106-5.
- Lo T, Lee Y, Tseng C-Y, Hu Y, Connelly MA, Mantzoros CS, Karp JM, Tavakkoli A. Daily transient coating of the intestine leads to weight loss and improved glucose tolerance. Metabolism. 2022;126:154917. doi:10.1016/j.metabol.2021.154917.
- Sikirica MV, Martin AA, Wood R, Leith A, Piercy J, Higgins V. Reasons for discontinuation of GLP1 receptor agonists: data from a real-world cross-sectional survey of physicians and their patients with type 2 diabetes. Diabetes Metab Syndr Obes. 2017;10:403–12. doi:10.2147/DMSO.S141235
- Centers for Disease Control and Prevention (CDC). National Diabetes Statistics Report. Atlanta (GA): U.S. Department of Health and Human Services; [cited 2025 Sep 13]
- World Health Organization. Obesity and overweight. Geneva: WHO; 2025 May 7 [cited 2025 Sep 5]. Available from:
- Heshmati K, Harris DA, Aliakbarian H, Tavakkoli A, Sheu EG. Comparison of early type 2 diabetes improvement after gastric bypass and sleeve gastrectomy: medication cessation at discharge predicts 1-year outcomes. Surg Obes Relat Dis. 2019;15(12):2025–2032. doi:10.1016/j.soard.2019.04.004. Epub 2019 Apr 22. PMID: 31711946.
- Buchwald H, Estok R, Fahrbach K, Banel D, Jensen MD, Pories WJ, et al. Weight and type 2 diabetes after bariatric surgery: systematic review and meta-analysis. Am J Med. 2009;122(3):248–256.e5. doi:10.1016/j.amjmed.2008.09.041
- Carlsson LMS, Peltonen M, Ahlin S, Anveden Å, Bouchard C, Carlsson B, et al. Durability of remission of type 2 diabetes after gastric bypass and sleeve gastrectomy: the Swedish Obese Subjects study. N Engl J Med. 2020;383(15):1443–1453. doi:10.1056/NEJMoa2003297
- Saeed L, Sharif G, Eda S, Raju Tullimalli I, Amin A, Riyalat AA, Alrashid FF, Abdelrahim AA. Comparative Effectiveness of Bariatric Metabolic Surgery Versus Glucagon-Like Peptide-1 Receptor Agonists on Cardiovascular Outcomes and Mortality: A Meta-Analysis. Cureus. 2024 Oct 17;16(10):e71684. doi: 10.7759/cureus.71684. PMID: 39552962;
- Stenberg E, Cao Y, Ottosson J, Hedberg S, Näslund E. Glycaemic and weight effects of metabolic surgery or semaglutide in diabetes dosage for patients with type 2 diabetes. Diabetes Obes Metab. 2024 Dec;26(12):5812-5818. doi: 10.1111/dom.15952. Epub 2024 Sep 18. PMID: 39295084.
By using this site, you acknowledge that all intellectual property rights in the website content, including but not limited to patents and trademarks, belong to AltrixBio. You agree not to use, reproduce, or distribute any material from this site without express authorization. AltrixBio will actively enforce its intellectual property rights to the fullest extent of the law.